サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1765390

遺伝子導入システムの世界市場

Gene Delivery Systems

出版日
ページ情報
英文 196 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
遺伝子導入システムの世界市場
出版日: 2025年07月09日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

遺伝子導入システムの世界市場は2030年までに62億米ドルに到達

2024年に43億米ドルと推定される遺伝子導入システムの世界市場は、2024年から2030年にかけてCAGR 6.5%で成長し、2030年には62億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるウイルス遺伝子は、CAGR 6.9%を記録し、分析期間終了時には41億米ドルに達すると予測されます。非ウイルス遺伝子セグメントの成長率は、分析期間でCAGR 6.2％と推定されます。

米国市場は12億米ドルと推定、中国はCAGR6.0%で成長すると予測

米国の遺伝子導入システム市場は2024年に12億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに9億6,740万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.8%と5.5%と予測されています。欧州では、ドイツがCAGR 4.9%で成長すると予測されています。

世界の遺伝子導入システム市場- 主要動向と促進要因のまとめ

遺伝子導入システムとは何か、なぜ現代医療に不可欠なのか？

遺伝子導入システムは、バイオテクノロジーと医学の分野で不可欠なツールであり、様々な病気を分子レベルで治療するために、細胞への遺伝物質の導入を可能にします。これらのシステムは、遺伝子治療、再生医療、ワクチン開発において重要な役割を果たしており、がん、遺伝性疾患、感染症などの疾患に対処しています。ウイルスベクター、リポソーム、ナノ粒子は、遺伝子導入システムで最も一般的に使用されている方法の一つであり、それぞれが異なる用途にユニークな利点を提供しています。個別化医療の分野が拡大していることは、個々の患者のニーズに合わせた正確な遺伝子介入を可能にするこれらのシステムの重要性をさらに強調しています。

技術革新はどのように遺伝子導入を進めているのか？

遺伝子導入における技術的進歩は、これらのシステムの能力と効率に革命をもたらしています。CRISPRベースのアプローチやエレクトロポレーションなど、非ウイルス性の送達方法における革新は、遺伝子治療の安全性と有効性を高めています。さらに、免疫系の活性化や限られたターゲティング能力といった従来の限界を克服できる合成ベクターの開発により、遺伝子導入の応用の可能性が広がっています。ナノ粒子工学の進歩は、遺伝子物質をより正確に送達し、制御された状態で放出することを可能にし、標的外への影響を減らし、患者の転帰を改善しています。これらの進歩により、遺伝子導入システムはより安全で、より効果的で、より広範な医療応用に適したものとなっています。

なぜ遺伝子治療ソリューションの需要が高まっているのか？

遺伝子治療ソリューションの需要は、慢性疾患や生命を脅かす疾患に対する永続的な治療法を提供する可能性があることから急増しています。遺伝学と分子生物学の研究が進むにつれて、遺伝子治療によって治療可能な疾患が増え、以前は不治の病と考えられていた症状にも新たな道が開かれつつあります。希少遺伝性疾患、がん、特定の感染症は遺伝子治療の主要なターゲットであり、成功には効果的な遺伝子導入システムが不可欠です。さらに、個別化医療の台頭により、特定のターゲットを絞った遺伝子改変を可能にするデリバリー・システムが推進されており、個々の遺伝子プロファイルに合わせた治療法を生み出すというヘルスケア業界の目標に合致しています。

遺伝子導入システム市場の成長の原動力は？

遺伝子導入システム市場の成長は、バイオテクノロジーの進歩、遺伝子治療に対する需要の増加、個別化医療への注目の高まりなど、いくつかの要因によってもたらされます。CRISPRや合成ベクター開発などの技術進歩により、より効率的で的を絞った遺伝子導入法が可能になり、治療可能な疾患の範囲が広がっています。遺伝子治療ソリューションが遺伝性疾患やがんの潜在的治療法として支持されるにつれ、効果的な送達システムの必要性が高まっています。さらに、精密医療が重視されるようになり、個々の患者に合わせた特定の制御された遺伝子介入を可能にするシステムが求められています。これらの要因が相まって、遺伝子導入システム市場は現代医療の礎石となりつつあります。

セグメント

デリバリー（ウイルス遺伝子、非ウイルス遺伝子、複合ハイブリッド）、アプリケーション（腫瘍学、中枢神経系、感染症、眼科、糖尿病、その他のアプリケーション）

調査対象企業の例

  • Amgen, Inc.
  • Bayer AG
  • Human Stem Cells Institute
  • Johnson & Johnson
  • Novartis AG
  • Oxford Biomedica plc
  • Pfizer, Inc.
  • Shanghai Sunway Biotech Co., Ltd.
  • Sibiono GeneTech Co. Ltd.

AIインテグレイションズ

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP16418

Global Gene Delivery Systems Market to Reach US$6.2 Billion by 2030

The global market for Gene Delivery Systems estimated at US$4.3 Billion in the year 2024, is expected to reach US$6.2 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Viral Gene, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the Non-Viral Gene segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 6.0% CAGR

The Gene Delivery Systems market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$967.4 Million by the year 2030 trailing a CAGR of 6.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.8% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Gene Delivery Systems Market - Key Trends & Drivers Summarized

What Are Gene Delivery Systems and Why Are They Essential in Modern Medicine?

Gene delivery systems are vital tools in the field of biotechnology and medicine, enabling the introduction of genetic material into cells to treat various diseases at a molecular level. These systems play a crucial role in gene therapy, regenerative medicine, and vaccine development, addressing conditions like cancer, genetic disorders, and infectious diseases. Viral vectors, liposomes, and nanoparticles are among the most commonly used methods in gene delivery systems, each offering unique benefits for different applications. The growing field of personalized medicine further underscores the importance of these systems, as they enable precise genetic interventions tailored to individual patients’ needs.

How Is Technological Innovation Advancing Gene Delivery?

Technological advancements in gene delivery are revolutionizing the capabilities and efficiency of these systems. Innovations in non-viral delivery methods, such as CRISPR-based approaches and electroporation, are increasing the safety and efficacy of gene therapies. Additionally, the development of synthetic vectors that can overcome traditional limitations, such as immune system activation and limited targeting capabilities, is expanding the potential applications of gene delivery. Advances in nanoparticle engineering allow for more precise delivery and controlled release of genetic material, reducing off-target effects and improving patient outcomes. These advancements are making gene delivery systems safer, more effective, and suitable for a broader range of medical applications.

Why Is There Growing Demand for Gene Therapy Solutions?

The demand for gene therapy solutions is surging due to their potential to offer lasting cures for chronic and life-threatening conditions. As research in genetics and molecular biology progresses, more diseases are becoming treatable through gene therapy, opening new avenues for conditions previously considered incurable. Rare genetic disorders, cancers, and certain infectious diseases are prime targets for gene therapy, where effective gene delivery systems are essential to success. Additionally, with the rise in personalized medicine, there is a push for delivery systems that allow specific, targeted genetic modifications, aligning with the healthcare industry’s goal of creating treatments tailored to individual genetic profiles.

What Drives the Growth of the Gene Delivery Systems Market?

The growth in the gene delivery systems market is driven by several factors, including advancements in biotechnology, increasing demand for gene therapies, and the rising focus on personalized medicine. Technological progress, such as CRISPR and synthetic vector development, has enabled more efficient and targeted gene delivery methods, expanding the range of treatable diseases. The need for effective delivery systems is growing as gene therapy solutions gain traction as potential cures for genetic disorders and cancers. Furthermore, the emphasis on precision medicine is pushing for systems that allow for specific, controlled genetic interventions tailored to individual patients. Collectively, these factors are propelling the gene delivery systems market forward as it becomes a cornerstone in modern medicine.

SCOPE OF STUDY:

The report analyzes the Gene Delivery Systems market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Delivery (Viral Gene, Non-Viral Gene, Combined Hybrid); Application (Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 46 Featured) -

  • Amgen, Inc.
  • Bayer AG
  • Human Stem Cells Institute
  • Johnson & Johnson
  • Novartis AG
  • Oxford Biomedica plc
  • Pfizer, Inc.
  • Shanghai Sunway Biotech Co., Ltd.
  • Sibiono GeneTech Co. Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Tariff Impact on Global Supply Chain Patterns
    • Gene Delivery Systems - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Gene Therapy in Treating Genetic Disorders
    • Advancements in Viral and Non-Viral Gene Delivery Technologies
    • Increased Focus on Targeted and Precision Medicine for Enhanced Therapeutic Efficacy
    • Expansion of Gene Delivery Applications in Oncology and Rare Diseases
    • Growing Adoption of CRISPR and Other Gene Editing Tools for Gene Therapy
    • Surge in Research Funding for Developing Novel Gene Delivery Methods
    • Increased Demand for Safer and More Efficient Gene Delivery Vehicles
    • Development of Nanoparticle-Based Gene Delivery Systems for Better Bioavailability
    • Rising Investment in Gene Delivery for Regenerative Medicine and Cell Therapy
    • Expansion of Clinical Trials Investigating Gene Delivery for Neurological Disorders
    • Growth in Partnerships Between Biotech Firms and Academic Institutions
    • Focus on Improving Patient Outcomes and Reducing Side Effects in Gene Therapy
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Gene Delivery Systems Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Gene Delivery Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Gene Delivery Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Gene Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Viral Gene by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Viral Gene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Non-Viral Gene by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Combined Hybrid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Combined Hybrid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Combined Hybrid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for CNS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for CNS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for CNS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Ophthalmology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Gene Delivery Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Gene Delivery Systems by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Gene Delivery Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for Gene Delivery Systems by Delivery - Viral Gene, Non-Viral Gene and Combined Hybrid Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of World 15-Year Perspective for Gene Delivery Systems by Delivery - Percentage Breakdown of Value Sales for Viral Gene, Non-Viral Gene and Combined Hybrid for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of World Historic Review for Gene Delivery Systems by Application - Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of World 15-Year Perspective for Gene Delivery Systems by Application - Percentage Breakdown of Value Sales for Oncology, CNS, Infectious Diseases, Ophthalmology, Diabetes and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION